1 - SYSTEMIC ANTIBACTERIAL AGENTS Flashcards

(264 cards)

1
Q

Owing to the increased prevalence of uncomplicated skin and soft tissue infections (USSTI) caused by community-acquired MRSA, there has been changes to the antibiotic prescribing pattern such that there is increase use of doxycycline, minocycline and bactrim (trimethoprim-sulfamethoxazole), and a decrease in the use of oral cephalosporin therapy

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Penicillins are bactericidal and inhibit synthesis of the bacterial cell wall

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Cephalosporins are bactericidal and inhibit synthesis of the bacterial cell wall

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Combination Beta-lactams (penicillins) and beta-lactamase inhibitor antibiotics are bactericidal and inhibit synthesis of the bacterial cell wall

A

True (amoxicillin-clavulanate, ticarcillin-clavulanate, piperacillin-clavulanate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Vancomycin is both bactericidal (against staphylococci and streptococci) and bacteriostatic (against most enterococci) against gram +Ve organisms only and inhibits synthesis of the bacterial cell wall

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Macrolides (clarithromycin, erythromycin, azithromycin) are bacteriostatic against most gram +Ve organisms except MRSA and enterococcus, as they inhibit bacterial protein synthesis

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fluoroquinolones are bactericidal against most gram -Ve organisms pseudomonas, enterobacteriaceae, bacillus anthrax (ciprofloxacin) and variable efficacy against gram +Ve organisms staph aureus and strep pyogenes (levofloxacin, moxifloxacin) by interfering with bacterial DNA replication

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tetracyclines (tetracycline, doxycycline, minocycline) are bacteriostatic in that they possess greater gram +Ve than gram -Ve activity by inhibiting bacterial protein synthesis

A

True (binding to 30s subunit of the bacterial ribosome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Rifampicin (a rifamycin antibiotic) is bactericidal with activity against mycobacteria and gram +Ve organisms and poor gram -Ve coverage by preventing bacterial protein synthesis

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The folate-synthesis inhibitor bactrim (trimethoprim-sulfamethoxazole) is bacteriostatic against many gram +Ve cocci, pseudomonas and PCP by inhibiting bacterial protein synthesis

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The Lincosamide Clindamycin is bacteriostatic against several gram +Ve cocci and a wide variety of anaerobes by reducing bacterial protein synthesis

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Penicillin G (IV and IM) and Penicillin V (PO) are first generation natural penicillins (bactericidal) with activity against gram +Ve cocci and rods, gram -Ve cocci and anaerobes, but are ineffective against MSSA and MRSA

A

True (dicloxacillin, nafcillin, oxacillin are semi-synthetic first generation penicillins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dicloxacillin, nafcillin, oxacillin are semi-synthetic first generation beta-lactamase resistant penicillins (bactericidal) exhibit activity against MSSA and other gram +Ve cocci such as streptococcus pyogenes, but MRSA developed subsequently

A

True (penicillin G and penicillin V are natural first generation penicillins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Amoxicillin and ampicillin (aminopenicillins) are second generation penicillins (bactericidal) with extended activity against gram -Ve bacilli

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Ticarcillin (carboxypenicillin) is a third generation extended spectrum penicillin (bactericidal) with anti-pseudomonal activity

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Piperacillin (ureidopenicillin) is a fourth generation extended spectrum penicillin (bactericidal) with anti-pseudomonal activity

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Amoxicillin-clavulanate and ampicillin-sulbactam are combination second generation/beta-lactamase inhibitors (bactericidal)

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Ticarcillin-clavulanate is a combination third generation carboxypenicillin/beta-lactamase inhibitor (bactericidal)

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Piperacillin-tazobactam is a fourth generation ureidopenicillin/beta-lactamase inhibitor (bactericidal)

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Staph aureus (gram +Ve coccus) and many enterobacteriaceae (gram -Ve rods) species bacteria produce beta-lactamase enzyme which hydrolyses beta-lactam penicillins (first generation semi-synthetic penicillins Dicloxacillin, nafcillin and oxacillin are beta-lactamase resistant), rendering these antibiotics ineffective

A

True (therefore some beta-lactam penicillins have been combined with a beta-lactamase inhibitor to produce resistance of the antibiotics to degradation by beta-lactamase enzyme)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

All beta-lactams (penicillins and cephalosporins) are excreted renally except nafcillin, oxacillin and piperacillin

A

True (nafcillin, oxacillin and piperacillin are eliminated through the biliary system)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Beta-lactams (penicillins and cephalosporins) are more commonly associated with drug-induced hypersensitivity reactions with the severity ranging from exanthematous eruptions, to urticarial eruptions to fatal anaphylaxis

A

True (Penicillin G is the first reported to cause a hypersensitivity reaction, with amoxicillin most commonly implicated agent more recently)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

A skin eruption that is not truly allergic in origin may arise when ampicillin is given to patients with infectious mononucleosis or lymphocytic leukaemia or when it is co-administered with allopurinol, therefore this unique ampicillin eruption is not believed to be a contraindication to treatment with other penicillins at a later date

A

True (the eruption is generalised, maculopapular and pruritic, and typically manifests within 7-10 days after the initiation of ampicillin with usual persistence for up to 1 week after ampicillin in discontinued)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

In patients with a history of severe and life-threatening allergic reaction to a penicillin or cephalosporin, avoidance of the other drugs in these 2 general categories is advised

A

True (for practical purposes it should be assumed that all penicillins cross-react, and that if they have a true allergic reaction to one form of penicillin they may react to all penicillins and possibly to cephalosporins as well)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
The aminopenicillins (amoxicillin and ampicillin) appear to be associated with a higher incidence of allergic reactions than other penicillins
True
26
GI upset including nausea and antibiotic-associated diarrhoea are not uncommon with penicillins
True (yoghurt or other means of lactobacillus ingestion may be a helpful adjuvant to prevent diarrhoea-related complications due to alterations in normal gut flora)
27
C. diff colitis can occur with penicillins
True
28
Shore nails (transverse leuconychia and onychomadesis/nail shedding following drug-induced erythroderma) have been seen with Dicloxacillin
True
29
Onychomadesis (nail shedding) and photo-onycholysis have been noted following dicloxacillin use
True
30
Cholestasis associated with penicillins is uncommon
True
31
Probenecid prolongs the renal excretion of penicillin and penicillin-beta lactamase antibiotics
True (result in an increase in serum concentration due to delayed renal excretion)
32
Oral antibiotics including beta-lactams (penicillins and cephalosporins) may potentially alter the anticoagulant effects of warfarin
True
33
Penicillins and cephalosporins are beta-lactam antibiotics
True
34
As oppose to penicillins which are also beta-lactams, the structure of beta-lactam cephalosporins gives it resistance to beta-lactamase enzymes
True
35
There are 5 generations of cephalosporins (beta-lactams) based on their general spectrum of antimicrobial activity
True
36
Cefazolin (IM/IV) and cephalexin (PO) are first generation cephalosporins which are most active of all the cephalosporins against gram +Ve staphylococci and non-enterococcal streptococci, and are active against many of the oral anaerobes except the Bacteroides fragilis group
True
37
Cefazolin (IM/IV) and cephalexin (PO) are first generation cephalosporins which are resistant to MRSA, streptococcus pneumoniae and gram -Ve organisms (haemophilus influenzae and enterococci, pseudomonas) and nosocomial gram -Ve infections
True
38
Cefuroxime (IV/IM/PO) and cefaclor (PO) are second generation true cephalosporins which demonstrate increased gram -Ve activity (against haemophilus influenzae, moraxella catarrhalis, neisseria meningitidis, neisseria gonorrhoea and some enterobacteriacea) and decreased gram +Ve activity
True (second generation cephamycins such as cefoxitin IV/IM are not 'true' cephalosporins and have inferior activity against gram +Ve staph and strep, but are effective against Bacteroides fragilis)
39
Third, forth and fifth generation cephalosporins have anti-pseudomonal activity
True
40
Third generation cephalosporins demonstrate less consistent activity against gram +Ve organisms and an increased spectrum of gram -Ve activity due to beta-lactamase stability, and some have anti-pseudomonal activity
True
41
Fifth generation cephalosporins have shown activity against MRSA, VRSA and MSSA and pseudomonas
True
42
Cephalexin (first generation cephalosporin) is best absorbed from an empty stomach
True
43
The bioavailability of Cefuroxime (second generation cephalosporin) is increased when taken with food
True (in contrast with first generation cephalosporin cephalexin where it is best absorbed from an empty stomach)
44
First and second generation cephalosporins including cephalexin are excreted primarily by the kidneys and dosage adjustments are recommended for patients with significant renal insufficiency
True
45
The short half life of cephalexin (less than 1 hour) may be associated with bacterial resistance if given less than TDS or QID dosing
True
46
GI effects such as nausea, vomiting, diarrhoea are relatively frequent with cephalosporins; although unlike its beta-lactam counterpart penicillins, antibiotic-associated C. diff colitis is much less common
True
47
Mild elevation of liver transaminases may occur with cephalosporins, although serious hepatic injury is rare
True
48
Potential cross-reactivity of cephalosporins with penicillins has been traditionally stated to occur in 5-10% of penicillin-allergic individuals, and cephalosporin-allergic reactions occur more commonly in patients with a history of penicillin allergy vs those without penicillin allergy
True (the degree of cross-reactivity likely depends on the generation of cephalosporin and very likely is due to the structural similarities/differences with penicillins I.e. In early first generation cephalosporins which sometimes contain trace amounts of penicillins)
49
Cephalosporin use should be avoided in patients with a history of an immediate or accelerated reaction to penicillin (IgE-mediated or severe type IV delayed hypersensitivity reactions)
True (cephalosporin skin testing is much less reliable than penicillin skin testing to evaluate hypersensitivity reactions)
50
Cephalosporin may cause vaginal candidiasis
True
51
Acute paronychia has been described following treatment with cephalexin
True
52
Drug-induced immune-mediated haemolytic anaemia have been associated with ceftriaxone (third generation cephalosporin) and piperacillin (forth generation penicillin)
True
53
Nephrotoxicity is rare in cephalosporins, but dose reduction of most cephalosporins is recommended in patients with renal insufficiency
True
54
Cephalosporins (such as the cephamycin antibiotic cefotetan) with the NMTT ring have been reported to induce a disulfiram-like reaction with alcohol ingestion
True
55
Cephalosporins (such as the cephamycin antibiotic cefotetan) with the NMTT ring can also prolong prothrombin times as it inhibits production of vitamin-K clotting factors and could be an issue in patients on anticoagulation therapy such as warfarin
True
56
Probenecid competes with renal tubular secretion of some cephalosporins and may increase and prolong the plasma levels for cephalosporins
True
57
Some cephalosporins may increase the risk of nephrotoxicity when co-administered with aminoglycosides (gentamicin) or potent diuretics
True
58
In patients with renal impairment, the half-life of beta-lactam/beta-lactamase combination of drugs is prolonged and blood levels are elevated, thus warranting dosage adjustment in some cases
True
59
The recommended oral agent for the treatment of animal or human bites infected by combined aerobic and anaerobic pathogens is amoxicillin-clavulanate
True
60
Adverse effects most often associated with amoxicillin-clavulanate and piperacillin-tazabactam are GI effects especially diarrhoea
True (diarrhoea occurs less frequently when amoxicillin-clavulanate is administered with food)
61
Hypersensitivity reactions from the beta-lactam/beta-lactamase antibiotics are similar to those seem from the beta-lactam (penicillins and cephalosporins) antibiotics alone
True
62
Ticarcillin and piperacillin can prolong bleeding times and cause platelet aggregation dysfunction
True
63
Ticarcillin and piperacillin can cause hypernatraemia, transient elevation of transaminases, thrombocytopenia, neutropenia and eosinophilia
True
64
Carbapenems (imipenem) demonstrate the most complete range of antibacterial coverage of any antibiotic class
True
65
There is a high degree of cross-reactivity between Carbapenems (imipenem) and penicillin
True (the incidence of allergic-type reactions to a carbapenem is 5.2 times greater in patient who were reportedly allergic to penicillin)
66
Monobactams (aztreonam) has an antibacterial spectrum activity limited to aerobic gram -Ve organisms and has been employed as a sole agent in treating gram -Ve cutaneous infections in conjunction with other drugs that inhibit gram +Ve or anaerobic flora
True
67
Monobactams (aztreonam) has an adverse effect profile similar to that of other beta-lactam antibiotics (penicillins and cephalosporins) including rare cases of erythema multiforme, TEN, urticarial eruptions and exfoliative dermatitis
True (however patients who are allergic to penicillin can be safely given aztreonam)
68
Patients who are allergic to penicillin can be safely given aztreonam
True
69
Vancomycin is clinically important in the treatment of MRSA
True
70
Vancomycin is administered IV because of minimal absorption from the GI tract and is used PO only for the treatment of C. Diff diarrhoea
True
71
90-100% of vancomycin is excreted by glomerular filtration in the kidneys, therefore dosage modification is recommended in patients with marked renal insufficiency
True
72
Red man syndrome and shock secondary to histamine release can be caused by rapid transfusion of vancomycin
True
73
Vancomycin is one of the most common causes of drug-induced linear IgA bullous dermatosis, developing after the initiation of vancomycin and also upon re-challenge
True (as vancomycin may rarely cause TEN, differentiation of TEN from vancomycin-induced linear IgA bullous dermatosis needs to be differentiated as multiple cases of vancomycin-induced linear IgA bullous dermatosis have been reported as these have presented as exanthematous eruption without blistering)
74
Vancomycin dose-related hearing loss/ototoxicity has been reported in patients with renal failure, likely due to reduced excretion of vancomycin leading to accumulation of the drug
True
75
Vancomycin has caused nephrotoxicity particularly when administered along with aminoglycoside antibiotics (gentamicin)
True
76
Macrolides have antibacterial and anti-inflammatory properties
True (anti-inflammatory properties contribute towards their therapeutic benefit in inflammatory facial dermatoses such as acne and Rosacea)
77
Erythromycin is the prototype macrolide
True (other macrolides which are in fact azalides include clarithromycin and azithromycin)
78
Clarithromycin and azithromycin are azalide antibiotics (class of macrolide antibiotics)
True
79
In the management of acne vulgaris, the use of oral erythromycin has markedly declined due to the widespread emergence of resistant P. acnes strains, with resistance rates as high as 50%
True
80
PO erythromycin has an erratic oral bioavailability and a short half-life requiring frequent administration
True
81
PO erythromycin is associated with frequent GI adverse effects such as nausea, abdominal discomfort and diarrhoea
True (erythromycin binds to motilin receptors throughout the GI tract, releasing motilin which stimulates migrating digestive contractions thus inducing a higher incidence of GI disturbance than with the azalide subcategory)
82
Erythromycin (and to a lesser extent clarithromycin) is a CYP3A4 and CYP1A2 inhibitor which leads to reduced clearance and increased risk of toxicity of a wide variety of drugs
True
83
Clarithromycin is 2-4 times more potent than erythromycin against gram +Ve organisms such as staphylococci and streptococci
True
84
Unlike erythromycin, clarithromycin and azithromycin possess increased activity against several gram -Ve pathogens including H. Influenzae
True
85
Both clarithromycin and azithromycin are affective against atypical mycobacteria such as Mycobacterium avium-intracellulare, Mycobacterium Leprae, and Mycobacterium chelonei
True (Clarithromycin is most effective against M. Leprae which causes leprosy)
86
Both clarithromycin and azithromycin demonstrate activity against Toxoplasma gondii, Treponema pallidum (cause of syphilis) and Borrelia burgdoferi
True
87
Azithromycin also has activity against organisms contracted from animal bites and human bites
True (similar to amoxicillin-clavulanate)
88
Azithromycin has activity against E. Coli, N. Gonorrhoea, chlamydia trachomatis
True
89
Unless administered in an enteric coated form, erythromycin is vulnerable to gastric acid inactivation and must be taken on an empty stomach
True
90
Clarithromycin and azithromycin (azalides class of macrolide antibiotics) have improved bioavailability than erythromycin with clarithromycin equally well absorbed with or without food, although azithromycin absorption in decreased with food
True
91
Both clarithromycin and erythromycin are excreted by the kidneys and dosages of both drugs warrant modification in significant renal failure
True (azithromycin is primarily metabolised and eliminated in the liver and so no adjustments are necessary in renal disease)
92
Selective use of azithromycin for acne vulgaris and Rosacea may be helpful in some patients who are intolerant to tetracyclines
True
93
Erythromycin is a rare cause of reversible hearing loss at high doses
True (ototoxicity reported at higher doses or in patients with hepatic or renal dysfunction as erythromycin liver metabolism and renal elimination is reduced in these patents leading to accumulation and increased serum levels of the drug)
94
Erythromycin is a a rare cause of skin eruptions and allergic reactions
True
95
Cardiac conduction abnormalities have been associated with macrolide use, and erythromycin carried the greatest risk of QT prolongation and torsades de pointes
True (risk of Cardiotoxicity increased with advanced age, higher dosages, rapid administration, and history of cardiac disease)
96
Clarithromycin may cause a metallic or bitter taste
True (also fixed drug eruption, leukocytoclastic vasculitis and hypersensitivity reactions)
97
Azithromycin has been associated with photosensitivity
True (also irreversible deafness, angioedema, hypersensitivity reactions and contact dermatitis)
98
Macrolide antibiotics (erythromycin, clarithromycin, azithromycin) have been associated with cholestatic hepatitis
True
99
There is increased risk of hypertrophic pyloric stenosis in infants exposed to macrolides through breast feeding mothers as these drugs are secreted into breast milk
True
100
Amiodarone (antiarrhythmic agent) may increase serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 inhibition
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism)
101
Fluoxetine (SSRI antidepressant) may increase serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 inhibition
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism)
102
Ketoconazole, itraconazole, fluconazole (azole antifungal agents) may increase serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 inhibition
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism)
103
Diltiazem and verapamil (calcium channel blockers) may increase serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 inhibition
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism) - nifedipine is not a CYP3A4 inhibitor
104
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels many drugs
True (mainly inhibit activity of CYP3A4 and to a lesser extent inhibit activity of CYP1A2)
105
Rifampicin (rifamycin antibacterial agents) may reduce serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 induction
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism)
106
Carbamazepine, valproate (anticonvulsants) may reduce serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 induction
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism)
107
Bexarotene (rexinoid type of retinoid) may reduce serum levels of erythromycin and clarithromycin (macrolides) through CYP3A4 induction
True (besides being a CYP3A4 inhibitor itself, erythromycin and clarithromycin is also subjected to CYP3A4 metabolism)
108
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of antiarrhythmic agents (amiodarone, flecainide) which are substrates of CYP3A4
True (QT prolongation and torsades de pointes)
109
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of warfarin which is a substrate of both CYP3A4 and CYP1A2
True (increased anticoagulant effect and risk of haemorrhage)
110
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of anticonvulsants (carbamazepine, valproate) which are substrates of CYP3A4
True
111
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of CsA which is a substrate of CYP3A4
True (increased risk of nephrotoxicity, neurotoxicity and hypertension)
112
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of Bexarotene which is a substrate of CYP3A4
True (Bexarotene is also a CYP3A4 inducer itself)
113
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of statins (Atorvastatin, lovastatin, Simvastatin) which are substrates of CYP3A4
True (increased risk of myopathy, rhabdomyolysis, hepatotoxicity)
114
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of theophylline which is a substrate of CYP1A2
True
115
Macrolides (erythromycin and Clarithromycin) inhibit the first pass Cytochrome P450 system in the liver and intestines, leading to decreased metabolic clearance and raised plasma levels and potential toxicity of certain benzodiazepines as these are substrates of CYP3A4
True
116
Ciprofloxacin and moxifloxacin (Fluoroquinolones) oral bioavailability is excellent and minimally affected by food
True (except norfloxacin) - therefore for most cutaneous infections parenteral therapy has no definitive advantage over the PO route
117
Ciprofloxacin and norfloxacin (fluoroquinolones) are mainly excreted renally and patients with significant renal impairment require dosage adjustment
True (except moxifloxacin)
118
Ciprofloxacin (fluoroquinolone) is the treatment of choice against cutaneous anthrax
True
119
Oral fluoroquinolone may be helpful in some cases of gram -Ve folliculitis, including persistent 'hot tub folliculitis' caused by pseudomonas aeruginosa
True (Isotretinoin may be needed for refractory cases and/or recurrences)
120
GI upset such as nausea, vomiting, diarrhoea is the most common adverse reactions associated with fluoroquinolones
True
121
Fluoroquinolones may cause CNS adverse effects I.e. Headaches, dizziness, agitation, sleep disturbances, seizures, psychotic reactions, hallucinations and depression
True (some of the CNS reactions may relate to fluoroquinolone antagonism of the GABA neurotransmitter)
122
Fluoroquinolone may impair cartilage formation based on animal studies, and this is generally avoided in children
True
123
Fluoroquinolone may cause delayed onset tendinitis and tendon rupture
True
124
Fluoroquinolones may cause hypersensitivity reactions with more serious anaphylactoid or anaphylactic reactions reported in Ciprofloxacin use
True
125
Fluoroquinolones may cause photosensitivity
True (evening dosing may minimise phototoxic potential)
126
Fluoroquinolones may cause photo-onycholysis
True
127
Blue-black pigmentation of the legs similar to minocycline dyschromia with demonstration of iron particles within the cytoplasm of dermal macrophages as been reported with perfloxacin fluoroquinolone therapy
True
128
Moxifloxacin fluoroquinolone has been associated with QT prolongation and torsades de pointes
True
129
All fluoroquinolones show decreased bioavailability when administered with calcium, aluminium and magnesium antacids + iron and zinc containing products; with a marked reduction in GI absorption likely due to chelation and the formation of cation-fluoroquinolone complexes that are poorly absorbed
True (patients to take the antibiotic at least 1-2 hours before, and not within hours after the ingestion of the above products)
130
Ciprofloxacin and other fluoroquinolones are CYP1A2 inhibitors
True
131
Fluoroquinolones increase the serum levels and potential toxicity of warfarin (CYP1A2 and CYP3A4 substrate) due to inhibition of CYP1A2
True
132
Fluoroquinolones increase the serum levels and potential toxicity of theophylline (CYP1A2 substrate) due to inhibition of CYP1A2
True
133
Tetracyclines exhibit a wide variety of direct and indirect anti-inflammatory properties that are unrelated to their antibiotic activity
True (acne vulgaris, Rosacea, immunobullous disease, sarcoidosis)
134
Tetracyclines inhibit the production of neutrophil chemoattractants by P. acnes
True (role in acne vulgaris)
135
Tetracyclines inhibit neutrophil migration
True
136
Tetracyclines inhibit granulomatous formation
True (role in sarcoidosis)
137
Alterations of the tetracyclines structure may alter its phototoxic potential, a dose-related phenomenon more commonly associated with doxycycline > tetracycline, and minimally from minocycline
True
138
Tetracycline is short acting and doxycycline + minocycline are long acting tetracyclines
True
139
The greatest prevalence of P. Acnes resistance is with tetracycline (as compared to doxycycline and minocycline)
True
140
Subantimicrobial dosing of doxycycline does not induce antibiotic-resistant bacterial strains
True
141
Tetracyclines are lipophilic allowing significant drug levels in the pilosebaceous unit, reaching high concentrations in skin and nails
True (order of lipophilicity is minocycline > doxycycline > tetracycline)
142
Tetracyclines can cross the blood-brain barrier
True (may cause pseudotumour cerebri)
143
Doxycycline is well absorbed regardless of food intake though a meal reduces GI absorption by 20%
True
144
Tetracycline is better absorbed in the fasting state
True
145
Minocycline immediate release formulation is well absorbed regardless of food intake
True (this is in contrast to the extended release formulation, which is better absorbed in a fasting state)
146
Dairy products (contain metallic cations such as calcium and magnesium), vitamin/mineral supplements antacids and antidiarrhoeal products can markedly reduce the GI absorption of tetracyclines through chelation of these drugs in the stomach
True (calcium, magnesium, aluminium, iron, zinc) - important to question patients about OTC products for indigestion, diarrhoea, or stomach upset which may reduce levels of the tetracyclines
147
GI side effects such as nausea, abdominal discomfort and 'pill oesophagitis' are more common with doxycycline
True (enteric coating of doxycycline has been shown to reduce GI adverse effects) - symptoms develop typically in the first few days, presenting most often as odynophagia, dysphagia, and retrosternal pain; and is usually avoidable with proper patient education to ingest with a large volume of water and not to take before reclining
148
Vestibular side effects are reduced with slower/extended release minocycline formulations as this side effect relates to the serum drug levels
True
149
Doxycycline is excreted primarily in the GI tract in bile and is acceptable for use in patients with renal failure, but caution is warranted in patients with severe liver disease
True (doxycycline not contraindicated in renal failure, unlike the other minocycline and tetracycline which are renally excreted and renal failure prolongs their half-life)
150
Doxycycline and minocycline have 2 main advantages over tetracycline for chronic inflammatory facial dermatoses (acne vulgaris, Rosacea, perioral dermatitis) - (1) less frequent dosing, (2) lower prevalence of less sensitive P. acnes strains
True
151
PO tetracyclines usually requires at least 3 weeks before initial visible improvement of chronic inflammatory facial dermatoses (acne vulgaris, Rosacea, perioral dermatitis) with maximum benefit between 3 and 6 months
True
152
Typically about 50% of patients with chronic inflammatory facial dermatoses (acne vulgaris, Rosacea, perioral dermatitis) relapse within 8 weeks of cessation of PO tetracyclines, often requiring additional courses
True
153
Doxycycline (and to a lesser extent tetracycline) is used in the treatment of papulopustular Rosacea, ocular Rosacea and perioral dermatitis (Rosacea variant), but does not improve erythematotelengiectatic Rosacea
True (reduces inflammatory lesions, perilesional erythema, and symptoms of stinging, burning, pruritus)
154
Pertinent to women with history of antibiotic-induced vaginal candidiasis, low dose doxycycline used for Rosacea is devoid of antibiotic selection pressure and is not associated with vaginal candidiasis in actively treated women
True
155
Tetracyclines (especially doxycycline) have been used most often in combination with nicotinamide for the treatment of immunobullous diseases such as bullous pemphigoid, linear IgA bullous dermatosis, Pemphigus vulgaris, Pemphigus foliaceus, benign familial Pemphigus/Hailey-Hailey disease, and cicatricial pemphigoid/mucous membrane pemphigoid
True
156
Tetracyclines may be useful in granulomatous diseases i.e. Doxycycline in cutaneous sarcoidosis, minocycline in silicone granuloma
True
157
Cetuximab-related acneiform cutaneous eruption responds to PO Minocycline and topical Tazarotene
True
158
Doxycycline and tetracycline is recommended in the treatment of syphilis in patients allergic to penicillin
True
159
Tetracyclines (most commonly doxycycline) can cause GI adverse effects including nausea, vomiting and abdominal discomfort
True
160
Even though diarrhoea is occasionally reported with tetracyclines, antibiotic-associated colitis due to C. Diff infection is rare
True
161
The presence of hiatus hernia may be a risk factor for 'pill oesophagitis' with doxycycline
True (pre-existing GORD is not a definitive risk factor)
162
Drug-induced hepatitis and pancreatitis are very uncommonly observed with various tetracyclines
True
163
Acute vestibular side effects presenting mainly as dizziness or vertigo (possibly with nausea and vomiting) are most common with minocycline immediate release formulations
True (typically occurs after the first dose or within a few days, are more common in women especially those of low body weight)
164
If acute vestibular side effects most commonly associated with minocycline immediate release formulation do not occur in the first few weeks of treatment, then they are not likely to occur later
True
165
Benign intracranial hypertension (pseudotumour cerebri) is an uncommon idiopathic reaction to the tetracyclines and persistence of this disorder can lead to severe loss of vision which may be permanent
True (headache and visual disturbances accompanied by nausea and/or vomiting)
166
Cutaneous phototoxicity and photo-onycholysis have been mainly reported with doxycycline use, mainly provoked by UVA but UVB may have a synergistic role
True (in contrast to minocycline which has been shown to exhibit negligible or absent phototoxicity potential) - prudent to educate patients on optimal photoprotection and avoidance of intentional natural and/or artificial UVA or UVB tanning
167
Minocycline has been shown to exhibit negligible or absent phototoxicity potential
True
168
Hyperpigmentation of skin, nailbeds, teeth, bone and mucous membranes including oral mucosa and sclera has been reported mainly with minocycline immediate release formulation, particularly with long term acne therapy
True (after cumulative dose of >70 g) - the formation of pigmentation was at sites of prior inflammation, trauma, areas of scar formation
169
Tetracycline has been associated with discolouration of adult teeth
True
170
Doxycycline has been associated with nail discolouration in paediatric patients, with features clinically, histologically, and ultrastructurally resembling those of long term high dose minocycline
True
171
Tetracyclines are contraindicated in children less than 9 years of age owing to yellow staining of teeth and possibly other adverse effects on the development of bones and teeth
True (especially tetracycline)
172
Tetracycline can precipitate vaginal candidiasis
True
173
Long term Tetracycline can precipitate gram -Ve acne or folliculitis
True
174
Tetracyclines may uncommonly cause hypersensitivity reactions including urticaria, fixed-drug eruption and drug-induced Sweets syndrome
True
175
Minocycline has been associated with serum sickness-like reactions especially in HIV patients and black African ethnicity
True (typically occur during first 1-2 months)
176
Doxycycline and minocycline have caused SJS
True
177
Minocycline has exclusively caused delayed autoimmune adverse reactions (autoimmune hepatitis), systemic lupus-like reactions and ANCA vasculitis
True (delayed for months to years)
178
Minocycline is the most common of the tetracyclines to cause drug hypersensitivity syndrome or drug reaction with eosinophilic and systemic symptoms (DRESS), with hepatitis being the most common component of the multisystem involvement
True
179
A lupus-like syndrome and other autoimmune adverse reactions appear to be unique to minocycline
True (sometimes with neutropenia)
180
Despite the propensity of minocycline causing a lupus-like syndrome, the emergence of a positive ANA during therapy does not equate to autoimmune disease as most patients with newly formed autoantibodies do not develop clinical disease
True
181
Minocycline may cause cutaneous polyarteritis nodosa (PAN) and vasculitis after 2-3 years of long term use
True
182
Minocycline may cause immune thrombocytopenia, presenting as Schamberg disease
True
183
Minocycline may cause neutropenia as a component of lupus-like syndrome
True
184
Tetracyclines at any time during pregnancy for inflammatory disorders is not recommended
True (and especially contraindicated in the second and third trimesters of pregnancy due to synthesis of fetal teeth and bones, congenital defects, maternal hepatotoxicity)
185
Tetracyclines ought to be avoided during lactation unless the benefits clearly outweigh the risks
True
186
Alcohol (chronic intake) increases doxycycline metabolism as alcohol is a Cytochrome P450 enzyme inducer
True (doxycycline metabolised and excreted in liver/bile)
187
Rifampicin (antiTB antibiotic) may reduce the levels of doxycycline due to increased metabolism by CYP3A4 induction
True (doxycycline is a substrate of CYP3A4)
188
Phenytoin, carbamazepine (anti-convulsants) may reduce the levels of doxycycline due to increased metabolism by CYP3A4 induction
True (doxycycline is a substrate of CYP3A4)
189
Quinalapril (ACE-inhibitor with high magnesium content) may reduce the GI absorption of tetracyclines due to chelation
True
190
Antacids (contain calcium, magnesium, aluminium) reduce the GI absorption of tetracyclines due to chelation
True
191
Cimetidine (H2 antihistamine) reduce the GI absorption of tetracyclines due to pH-dependant inhibition of drug dissolution
True
192
Other chelating drugs including iron, zinc, bismuth salts reduce the GI absorption of tetracyclines due to chelation
True
193
Bile acid sequestrants (cholestyramine) reduce the GI absorption of tetracyclines
True
194
Tetracyclines may increase the serum levels and potential toxicity of warfarin due to tetracyclines-induced changes in gut flora affecting enterohepatic recirculation of warfarin
True
195
Tetracyclines may increase the serum levels and potential toxicity theophylline (xanthine oxidase inhibitor)
True
196
Tetracyclines may increase the serum levels and potential toxicity of digoxin
True
197
Tetracyclines may reduce the serum levels and efficacy of hormonal contraceptives as they theoretically inhibit enterohepatic recirculation of Oestrogens
True
198
Tetracyclines may potentially increase the photosensitivity of St John's wort
True (doxycycline and tetracycline may cause photosensitivity in their own right)
199
Tetracyclines may potentially increase the photosensitivity of porphyrins I.e. ALA used in PDT
True (doxycycline and tetracycline may cause photosensitivity in their own right)
200
Tetracyclines may potentially increase the photosensitivity of psoralens (used in PUVA therapy)
True (doxycycline and tetracycline may cause photosensitivity in their own right)
201
Tetracyclines may potentially increase the photosensitivity of retinoids (reduce stratum corneum thickness)
True (doxycycline and tetracycline may cause photosensitivity in their own right)
202
Concomitant use of tetracyclines and oral retinoids may increase the risk of benign intracranial hypertension (pseudotumour cerebri)
True (both drug classes independently cause this adverse effect)
203
When used for atypical mycobacterial infections or leprosy, rifampicin is administered in combination with other anti-TB drugs and can be used over several months
True
204
Rifampicin has been used in combination with either Clindamycin or Bactrim (trimethoprim-sulfamethoxazole) when treating CA-MRSA
True (resistance of staph aureus strains develops rapidly when rifampicin monotherapy is used)
205
GI absorption of rifampicin may be reduced by approximately 1/3 when ingested with food
True
206
Rifampicin induces its own liver metabolism
True (Cytochrome P450 inducer)
207
30% of rifampicin is excreted in the kidneys
True
208
Although rifampicin crosses the placenta, it is not a particular teratogen although if used in the last few weeks of pregnancy can cause haemorrhagic disease of the newborn and mother which requires prophylactic vitamin K
True
209
Rifampicin is a potent inducer of multiple Cytochrome P450 Isoforms including CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4
True
210
Rifampicin is intensely red in colour and highly lipophilic with widespread body distribution and causes harmless orange-red discolouration of liquid body excretions (urine, sweat, tears, breast milk) a few hours after ingestion of a dose and light staining of fabric and permanent staining of soft contact lenses sometimes observed
True
211
Rifampicin has been associated with CNS symptoms including headache, drowsiness, ataxia, dizziness, inability to concentrate and fatigue
True
212
Rifampicin has been associated with GI effects including epigastric distress, nausea, vomiting and diarrhoea
True
213
C. Diff antibiotic-associated colitis has been rarely reported with Rifampicin use
True
214
Rifampicin used intermittently and in high doses has rarely cause immunogenicity effects leading to the formation of rifampicin-mediated antibodies
True (minor cutaneous, GI, and influenza-like syndromes or more severe thrombocytopenia, haemolytic anaemia, acute renal failure and immunobullous diseases)
215
Rifampicin may be associated with asymptomatic changes in LFTs especially transaminases and possibly hyperbilirubinaemia, although symptomatic hepatotoxicity is more likely when rifampicin is used in combination with isoniazid
True (dosage reduction may be needed in patients with severe hepatic impairment)
216
Use of rifampicin in patients with impaired liver function warrants careful clinical assessment and lab monitoring of LFT
True (rifampicin induces its own metabolism in the liver)
217
Patients on rifampicin are at increased risk of developing DVT
True
218
Rifampicin may exacerbate porphyria due to induction of the enzyme delta-aminolevulenic acid synthetase and should be avoided in this patient population
True
219
Rifampicin may cause pulmonary fibrosis
True
220
Rifampicin may cause ocular toxicity
True
221
Rifampicin causes increased clearance of oral contraceptives leading to decreased efficacy and unintended pregnancy
True (CYP inducer causing increased drug clearance)
222
Rifampicin causes decreased anticoagulant effects of warfarin leading to reduced ability to achieve therapeutic INR levels
True (CYP inducer causing increased drug clearance)
223
Rifampicin causes reduced antifungal activity of azole antifungal agents leading to persistence of infection
True (CYP inducer causing increased drug clearance)
224
Rifampicin causes decreased serum levels of several HMG CoA-reductase inhibitors (CYP3A4 substrates Simvastatin, lovastatin, Atorvastatin) leading to loss of cholesterol control
True (CYP inducer causing increased drug clearance)
225
Rifampicin causes reduction of CsA or tacrolimus serum levels leading to decreased immunosuppressive effect and therapeutic failure
True (CYP inducer causing increased drug clearance)
226
Concomitant antacid ingestion may reduce GI absorption of rifampicin
True (rifampicin given 1 hour before antacid intake)
227
The half-lives of TMP-SMX (Bactrim) may be prolonged in the presence of marked renal insufficiency due to renal excretion
True (dosage adjustment is warranted for patients with renal insufficiency)
228
TMP-SMX (Bactrim) is distributed into breast milk and cross the placenta
True
229
TMP-SMX (Bactrim) is partially bio-transformed via hepatic metabolism
True
230
30-60% of TMP and 20-40% of SMX in Bactrim is renally excreted
True
231
GI adverse effects can be associated with TMP-SMX (Bactrim) including nausea, vomiting and loss of appetite
True
232
CNS adverse effects can be associated with TMP-SMX (Bactrim) including cephalgia, dizziness and tinnitus
True
233
Antibiotic-associated colitis due to C. Diff has been reported with TMP-SMX (Bactrim)
True
234
TMX-SMX (Bactrim)-induced cutaneous eruptions including exanthematous and urticarial eruptions and/or pruritus may be seen in 4-5% of healthy patients and approximately 15% of HIV-infected patients, usually manifesting within 1-2 weeks after starting therapy
True
235
Sulfonamide-related drug hypersensitivity syndrome, SJS, TEN and haematologic reactions (agranulocytosis) are adverse effects of greatest concern with TMP-SMX
True
236
In most cases, drug hypersensitivity syndrome or SJS/TEN manifest within the first 2-6 weeks after starting TMP-SMX (Bactrim)
True (patients should be told to discontinue treatment if they develop flu-like symptoms, arthralgias, or painful skin)
237
TMP-SMX (Bactrim) should be avoided in patients with first-degree relatives who have experienced drug hypersensitivity syndrome or SJS/TEN associated with sulfonamide use and in those that have a prior sulfonamide allergy
True
238
Uncommonly haematologic reactions associated with TMP-SMX (Bactrim) are thrombocytopenia, neutropenia, hypopothrombinaemia, aplastic anaemia/pancytopenia, and pure red cell aplasia
True
239
TMP-SMX (Bactrim) may cause haemolytic anaemia in patients with G6PD deficiency
True (sulfonamide adverse effect)
240
TMP-SMX (Bactrim) should be used very cautiously in patients with a possible folate deficiency or in those with pre-existing megaloblastosis as it has been suggested that megaloblastosis may predispose patients to some haematopoetic adverse effects with exposure to TMP-SMX (Bactrim)
True
241
TMP-SMX (Bactrim) may also cause pustular skin eruptions
True
242
TMP-SMX (Bactrim) may also cause drug-induced Sweet's syndrome
True
243
TMP-SMX (Bactrim) may cause nail changes including Beau's lines, paronychia, partial leukonychia, and photo-onycholysis
True
244
Breastfeeding should be avoided in patients taking TMP-SMX (Bactrim) as premature infants and those with hyperbilirubinaemia should not be exposed to TMP-SMX (Bactrim) via breast milk as SMX competes with bilirubin binding to plasma albumin
True
245
TMP-SMX (Bactrim) increases dapsone levels warranting closer monitoring of dapsone toxicity (myelosuppression and methaemoglobinaemia)
True
246
TMP-SMX (Bactrim) increases the risk of blood dyscrasias in patients on MTX
True
247
Reversible nephrotoxicity has been reported in renal transplant patients concomitantly on TMP-SMX (Bactrim) and CsA and avoidance of co-administration if clinically feasible is preferred
True
248
Resistance to Clindamycin generally can confer resistance to macrolides (erythromycin)
True
249
Clindamycin is well absorbed orally independent of food with wide tissue distribution
True
250
Clindamycin is highly protein bound, is metabolised predominantly in the liver and excreted in the urine as inactive metabolites
True (the plasma half-life is raised slightly with severe renal or hepatic failure) - dosage adjustment is necessary in liver failure as protein synthesis and binding is affected, although no dosage adjustment is needed in renal failure patients
251
Concern regarding the risk of antibiotic-associated colitis has markedly limited Clindamycin use in acne vulgaris patients
True (though still used in cellulitis, folliculitis, furunculosis, carbuncles, impetigo, ecthyma and hidradenitis suppurativa)
252
Other GI adverse effects associated with Clindamycin include nausea, vomiting and elevated transaminases
True
253
Clindamycin may rarely cause bone marrow suppression
True
254
Clindamycin may rarely cause renal impairment
True
255
Clindamycin has been associated with exanthematous or urticarial eruptions, anaphylaxis, erythema multiforme, SJS-type reaction with polyarthritis
True
256
Clindamycin is not teratogenic
True
257
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the effect of other neuromuscular agents
True
258
The usual adult dose of Clindamycin is 150mg - 300mg BD although hidradenitis suppurativa may require 300mg TDS
True
259
Antibiotics eliminated through the biliary system include: (1) Piperacillin (Penicillin) (2) Nafcillin (Penicillin) (3) Oxacillin (Penicillin) (4) Moxifloxacin (Fluoroquinolone) (5) Azithromycin (Macrolide) (6) Doxycycline (Tetracyclines)
True (all other antibiotics are eliminated through the kidneys)
260
The following antibiotic groups are susceptible to chelation in the GI tract (causing reduced absorption and bioavailability) when concomitantly administered with calcium, magnesium, zinc, iron, bismuth salts: (1) Fluoroquinolones (Ciprofloxacin, Moxifloxacin, Norfloxacin) (2) Tetracyclines (Tetracycline, Doxycycline, Minocycline)
True
261
Dose reduction should be considered for the following antibiotics in the setting of renal insufficiency: (1) Penicillins (2) Cephalosporins (3) Vancomycin (4) Erythromycin and Clarithromycin (Macrolides) (5) Ciprofloxacin and Norfloxacin (Fluoroquinolones) (6) Tetracycline and Minocycline (Tetracyclines) - use with caution (7) Bactrim/TMP-SMX
True (renally excreted) The following are safe in renal impairment due to bile excretion: Azithromycin (Macrolide) Moxifloxacin (Fluoroquinolone) Doxycycline (Tetracyclines) N.B. Even though Clindamycin is really excreted, no dosage adjustment is needed in renal failure patients
262
Dose reduction should be considered for the following antibiotics in the setting of liver disease: (1) Rifampicin - risk of toxicity as it is an inducer of its own liver metabolism (2) Clindamycin - increase serum free drug in liver disease as it is highly plasma protein bound and liver disease affects plasma protein synthesis
True
263
The following antibiotics are nephrotoxic/may cause renal impairment: (1) Vancomycin (particularly when co-administered with gentamicin) (2) Gentamicin (3) Clindamycin (4) Bactrim/TMP-SMX (when co-administered with CsA)
True
264
The following antibiotics are best absorbed from an empty stomach: (1) Cephalexin (2) Erythromycin (non-enteric coated) (3) Extended release Minocycline (but not the immediate release formulation) (4) Rifampicin (also sensitive to antacids which reduces its absorption)
True | NB. In contrast, Cefuroxime bioavailability is increased with food intake